Phase II Trial Opens: Telemedicine-Delivered Prolonged Exposure Therapy for PTSD in Opioid Use Disorder — What Clinicians Need to Know

References

1. 1.Hien, D. A., Levin, F. R., Ruglass, L. M., López-Castro, T., Papini, S., Hu, M. C., Cohen, L. R., Herron, A., & Schäfer, I. (2015). Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial. Journal of Consulting and Clinical Psychology, 83(2), 359-369. https://doi.org/10.1037/ccp0000068
2. 2.Imel, Z. E., Laska, K., Jakupcak, M., & Simpson, T. L. (2013). Meta-analysis of dropout in treatments for posttraumatic stress disorder. Journal of Consulting and Clinical Psychology, 81(3), 394-404. https://doi.org/10.1037/a0031474
3. 3.Mills, K. L., Teesson, M., Back, S. E., Brady, K. T., Baker, A. L., Hopwood, S., Sannibale, C., Barrett, E. L., Merz, S., Rosenfeld, J., & Ewer, P. L. (2012). Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. JAMA, 308(7), 690-699. https://doi.org/10.1001/jama.2012.9071
4. 4.Roberts, N. P., Roberts, P. A., Jones, N., & Bisson, J. I. (2015). Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: A systematic review and meta-analysis. Clinical Psychology Review, 38, 25-38. https://doi.org/10.1016/j.cpr.2015.02.007
5. 5.University of Vermont. (2024). Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD. ClinicalTrials.gov. NCT06288711. https://clinicaltrials.gov/study/NCT06288711
6. 6.Weathers, F. W., Blake, D. D., Schnurr, P. P., Kaloupek, D. G., Marx, B. P., & Keane, T. M. (2013). The clinician-administered PTSD scale for DSM-5 (CAPS-5). Interview available from the National Center for PTSD. https://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp